Form 4: Avantor EVP Gourdier Granted Significant Equity Awards

Avantor, Inc. EVP Benoit Gourdier received substantial grants of restricted stock units and stock options, alongside a tax-related share disposition.

Summary

• Benoit Gourdier, EVP, Bioscience & Medtech at Avantor, Inc. (AVTR), reported recent equity transactions.
• On February 19, 2026, Gourdier was granted 134,364 shares of common stock as restricted stock units (RSUs), which will vest in three equal annual installments starting February 19, 2027.
• On the same date, Gourdier was granted 528,848 stock options with an exercise price of $11.05, vesting in three equal annual installments beginning February 19, 2027, and expiring February 19, 2036.
• On February 20, 2026, 4,160 shares of common stock were disposed of at $9.03 per share to cover tax withholding obligations related to RSU vesting.
• Following these transactions, Gourdier beneficially owns 365,888 shares of common stock and 528,848 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management's interests with long-term shareholder value through equity grants.

Positives

• Grant of 134,364 restricted stock units (RSUs) to a key executive, aligning management's interests with shareholder value.
• Grant of 528,848 stock options with an exercise price of $11.05, providing an incentive for future stock price appreciation.

Negatives

• Disposition of 4,160 shares of common stock at $9.03 to cover tax withholding obligations, which is a standard practice but reduces direct share ownership.

Future Outlook

The granted restricted stock units and stock options are structured to vest in three equal annual installments beginning February 19, 2027, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that executive equity grants, such as RSUs and stock options, are common compensation practices in the bioscience and medtech sectors, aiming to retain key talent and align executive incentives with long-term company performance. This particular filing reflects a standard compensation event for a senior executive.

Comparison to Industry Standards

• Executive compensation packages, including significant equity grants, are standard across large-cap companies in the life sciences and medical technology industries.
• Similar grants are observed at companies like Danaher Corporation or Thermo Fisher Scientific, where executive incentives are heavily tied to long-term stock performance and strategic milestones.
• The vesting schedule over three years is also a common structure designed to promote executive retention and sustained performance.

Stakeholder Impact

• Shareholders: The equity grants align the executive's financial interests with long-term shareholder value, potentially incentivizing performance that benefits the stock price.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The restricted stock units will begin vesting in three equal annual installments starting February 19, 2027.
• The stock options will begin vesting in three equal annual installments starting February 19, 2027.
• The stock options will expire on February 19, 2036.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants and a tax-related share disposition. While the grants are a positive for executive alignment, they are standard practice and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as it reflects no significant new catalysts for a buy or sell decision based solely on this filing.

Keywords

Avantor, AVTR, Benoit Gourdier, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Bioscience, Medtech